By: IPA posted on: January 14, 2009

Since the first market approval of Myozyme, the IPA has liaised directly with Genzyme LSD Therapeutics to insist that an adequate inventory of the product was kept to ensure continuous supply to all patients receiving the treatment; whether through their commercial or compassionate-use programs. Regretfully, in July 2008 Genzyme released a notification that supply would be tight in 2009 until a larger-scale production facility in Belgium is approved by the European Medicines Agency (EMEA).